ARCS Australia appoints Commercial Eyes Founder and Managing Director to Board.
ARCS Australia has appointed Commercial Eyes Founder and Managing Director, Andrew Carter, to its Board of…
Latest Insights
Commercial Eyes at PharmAus19
It is a privilege for the Commercial Eyes team to work closely with so many of the companies represented at PharmAus, to play a key role in making their innovations…
Educating and empowering Indigenous children through Yalari
Commercial Eyes is honoured to be able to provide ongoing support to educating Indigenous children through…
Leukaemia Foundation – Raising Awareness of Blood Cancers
Through various parts of our business including market access and insights, regulatory services and medical communications, Commercial Eyes works with a number of organisations involved in improving and extending the…
No CE mark? No problem.
Changes to legislation have increased flexibility for Sponsors looking to market medical devices in…
Patient programs for improved patient outcomes
In the digital age of present, patients have never been better equipped with the devices and technologies to take control of their own healthcare needs and outcomes….
Are you ready for the mandatory transition to eCTD for prescription medicines?
A staged implementation has been proposed for prescription medicines to reflect the current industry uptake of the eCTD format. The transition begins with new chemical entity, new biological entity, biosimilar…
Making the most of complementary medicines reforms
In March this year the TGA finally started rolling out the long awaited Complementary Medicine…
The long road to PBS listing for Orkambi
With its recent stint on Sunrise, Orkambi is a high-profile example of what can occur when both the PBAC and the sponsor are unable to reach agreement on the value of a…
Life Saving Drugs Program: new lease on life, or on life support?
The Life Saving Drugs Program currently provides subsidised access to patients with rare and life-threatening conditions to essential and very expensive medicines….
What is Happening with the Provisional Approval Pathway?
When the independent review of medicines and medical devices regulation was announced the pharmaceutical sector immediately saw the opportunity for an expediated approval pathway for certain prescription…
New ‘SmPC’ Format for the Australian Product Information
The TGA have published a new form for providing the product information (PI) which means more work for regulatory teams but an enhancement of the quality use of medicines for Australian patients….